Cancer

Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, US Food Sovereignty Alliance, Cancer, Biotechnology, Technology, Control, List of life sciences, German Cancer Research Center, ADC, Partner, NRW.Bank, Food, Antibody, Idinvest Partners, Contributor License Agreement, Company, CEO, Therapeutic index, FWB, Therapy, CNRS, Investor, Fine chemical
Thursday, October 21, 2021 - 9:00am

Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.

Key Points: 
  • Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.
  • This technology has the potential to widen the therapeutic index of an ADC and to make our Nectin-4 ADC a best-in-class.
  • Pursuant to the agreement, Mablink Bioscience is entitled to receive milestone and royalty payments, based on the development of the Nectin-4 ADC.
  • Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high-need cancers.

Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma

Fast track (FDA), Priority review, Head, Melanoma, Cancer, Reverse transcriptase, Neoplasm, Ipilimumab, OSE, Fast Track, TET, CET, Patient, FDA, Ovarian cancer, ORR, Review, Communication, Webcast, EST, Nivolumab, Biologics license application, Immune system, CD4, GLOBE, Accelerated approval (FDA), Pembrolizumab, Frontiers, Physician, Mesothelioma, Cryptocurrency, Pharmaceutical industry
Thursday, October 21, 2021 - 7:05am

Ultimovacs senior management will host a webcast on the Fast Track designation and the supporting clinical data at 13.00 CET on Thursday, October 21.

Key Points: 
  • Ultimovacs senior management will host a webcast on the Fast Track designation and the supporting clinical data at 13.00 CET on Thursday, October 21.
  • Fast Track designation enables early and frequent communication with the FDA to support the drugs development, as well as entitlement to a Rolling Review of the Biologic License Application.
  • Drugs with Fast Track designation may also be considered for Accelerated Approval and Priority Review provided certain criteria are met.
  • We are delighted UV1 has received the Fast Track designation and look forward to working more closely with the FDA to bring UV1 to melanoma patients as soon as possible, said Carlos de Sousa, Chief Executive Officer of Ultimovacs.

Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates

Biotechnology, Health, Science, Pharmaceutical, Research, Fibrosis, Research, Volvo Business Units, Technology, Cancer, Industry, Ipsen, Connective tissue, Patient, Pharmacology, Bristol Myers Squibb, UCB, Precision medicine, CSO, Patent, Company, Pulmonary fibrosis, CEO, Degenerative disease, Tissue, Solution, Artificial intelligence, NASH, BMS, Heart, Liver, Fine chemical, Pharmaceutical industry
Thursday, October 21, 2021 - 7:00am

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Key Points: 
  • Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
  • Also, TiumBio has secured an exclusive option to in-license global development and commercialization rights of the discovered drug candidates after their evaluation upon reaching predefined success criteria.
  • Philippe Genne, CEO and founder of Oncodesign, said: This new collaboration with TiumBio, an expert company in fibrosis in South-Korea, further expands the global reach of our unique technologies.
  • It is believed that this joint R&D collaboration, signed by TiumBio, which has strengths in fibrosis R&D, can be a catalyst to spur the development of fibrosis treatment.

MDxHealth Provides Q3-2021 Business Update

Bachelor of Arts, Diagnosis, University, Prognosis, Cancer, University of North Carolina School of the Arts, LabCorp, Genetics, Patient, Quest Diagnostics, Methylation, Physician, Don, Social media, Chapel Hill, Company, CEO, Growth, Nasdaq, Prostate cancer, Management, Medical imaging
Thursday, October 21, 2021 - 6:00am

From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company.

Key Points: 
  • From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company.
  • Michael K. McGarrity, CEO of MDxHealth commented: We are very excited to welcome Don Hardison to our board of directors.
  • Dons breadth of experience and reach into the U.S. and global diagnostic industry will serve MDxHealth well as we go forward.
  • MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021

Degenerative disease, Euronext, CET, Investor, Cancer, Webcast, Pharmaceutical industry
Thursday, October 21, 2021 - 6:00am

Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 28, 2021 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2021 financial results and provide a business update.

Key Points: 
  • Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 28, 2021 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2021 financial results and provide a business update.
  • A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors .
  • A replay of the webcast will be available on the argenx website for approximately one year following the call.
  • Please dial in 15 minutes prior to the live call.

Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)

Head, Financial condition report, Melanoma, U.S. Securities and Exchange Commission, Securities Act of 1933, CpG, LinkedIn, Cancer, Merkel-cell carcinoma, Drug development, Twitter, File, Analysis, Security (finance), Patient, Founder, Investor, Private Securities Litigation Reform Act, Result, TLR9, Review, Jefferies, Social media, Annual report, Forward-looking statement, Webcast, COVID-19, Checkmate, FACP, Nasdaq, Justice and Security Act 2013, Research, Immune system, Q&A, GLOBE, Vaccine, Pharmaceutical industry
Wednesday, October 20, 2021 - 9:30pm

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced a live webcast on innate immune modulators and vidutolimod (CMP-001) hosted by Jefferies on Tuesday, October 26 from 11:00am – 12:00pm ET.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced a live webcast on innate immune modulators and vidutolimod (CMP-001) hosted by Jefferies on Tuesday, October 26 from 11:00am 12:00pm ET.
  • in a scientific discussion of the role of innate immune modulators in cancer treatment.
  • An archived copy of the webcast will be available on the Checkmate website for approximately 90 days after the event.
  • Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.

NANOBIOTIX Provides Third Quarter Operational and Financial Update

Oncology, Health, Technology, Nanotechnology, Pharmaceutical, Biotechnology, Safety, Liver disease, Neoplasm, Twitter, Partnership, Mall of America, Lung, Radiation, Life, Nasdaq, Trial of the century, COVID-19, Company, PFS, Nanotechnology, Nanoparticle, AMF, Radiation therapy, Monroe Dunaway Anderson, Private Securities Litigation Reform Act, Biology, U.S. Securities and Exchange Commission, Cancer, Annual report, University, Investment, Nivolumab, Central nervous system, NBTXR3, Cetuximab, III, MD Anderson Cancer Center, SEC, Risk, Â, HNSCC, Population, NANO, Annual general meeting, Poster, LinkedIn, Patient, NASDAQ, Forward-looking statement, Metastasis, Canadian International Council, Pharmaceutical industry, Medical imaging
Wednesday, October 20, 2021 - 9:15pm

Nanobiotix reported cash, cash equivalents, and short-term investments totaling 89.8 million as of September 30, 2021, compared to 119.2M as of December 31, 20201.

Key Points: 
  • Nanobiotix reported cash, cash equivalents, and short-term investments totaling 89.8 million as of September 30, 2021, compared to 119.2M as of December 31, 20201.
  • Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.
  • 1 It being specified that the company did not generate any revenue during the third quarter of 2021, this following the termination of the PharmaEngine partnership.

Guardant Health Appoints Myrtle Potter to Its Board of Directors

Health, Oncology, Medical Devices, Liberty Mutual, University, University of Chicago, Cancer, Knowledge, Industry, Amazon (company), Merck, Bristol Myers Squibb, Patient, Helmy Eltoukhy, Trustee, Bachelor, Vant, Commercial Operating System (COS), LLC, Company, Board, Health, Medco Health Solutions, Roivant Sciences, Therapy, AstraZeneca, GH, Board of directors, Pharmaceutical industry
Wednesday, October 20, 2021 - 9:30pm

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors.
  • We are very pleased to welcome Myrtle Potter to our Board of Directors as we continue to build and deliver on our mission of conquering cancer with data, said Helmy Eltoukhy, Guardant Health Co-CEO and Chairman of the Board.
  • I am thrilled to be joining Guardant Healths Board of Directors at such a significant time for the company, said Myrtle Potter.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Direct Relief Triples Pharmaceutical Cold Chain Capacity as Global Demand Surges

People, COVID-19, Freezing, Research, Technology, Vacuum, Cancer, Direct Relief, Vaccination, Patient, Transport, Insulin, FDA, Refrigeration, Time, Medicine, Health, Growth, Multimedia, Diabetes, Temperature, Hurricane Ida, Water, Warehouse, Pharmaceutical industry
Wednesday, October 20, 2021 - 9:12pm

SANTA BARBARA, Calif., Oct. 20, 2021 /PRNewswire/ -- Direct Relief is meeting surging demand for refrigerated medications by nearly tripling its pharmaceutical refrigeration capacity.

Key Points: 
  • SANTA BARBARA, Calif., Oct. 20, 2021 /PRNewswire/ -- Direct Relief is meeting surging demand for refrigerated medications by nearly tripling its pharmaceutical refrigeration capacity.
  • Direct Relief's existing cold storage room, a 2,900-square-foot facility that opened in 2018 at its California headquarters, is already full much of the time.
  • Direct Relief invested $1.5 million to build and equip the new cold room and is now working to increase its existing solar and battery capacity to help offset the room's energy needs.
  • Global cold chain pharmaceutical production is forecasted to grow 48% between 2018 and 2024, vs. 27% growth in room-temperature pharmaceutical production, according to Pharmaceutical Commerce.

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies

Science, Head, Actinium-225, Bladder cancer, Association, Cancer, Neoplasm, DNA, Merck, Colorectal cancer, Radionuclide, FGFR3, Patient, TAT, Private Securities Litigation Reform Act, Radiopharmaceutical, View, Hereditary diffuse gastric cancer, GMP, SEC, Nuclear medicine, Neurotensin receptor, Company, Risk, McMaster University, Tat, Isotope, Multimedia, IND, Fusion, NTSR1, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Good manufacturing practice, AstraZeneca, Population, Pembrolizumab, Neck, Pharmaceutical industry, Vaccine, Medical imaging
Wednesday, October 20, 2021 - 9:05pm

HAMILTON, Ontario and BOSTON, Oct. 20, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies (TATs) at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.

Key Points: 
  • These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.
  • Data from preclinical studies of FPI-1966, a TAT designed to target and deliver actinium-225 to cancer cells expressing FGFR3, were presented in an oral presentation titled, "FGFR3 Targeted Alpha Therapeutic [225Ac]-FPI-1966 induces regression in preclinical bladder xenograft model".
  • Further, the data showed therapeutic efficacy of FPI-1966 at both single and multiple doses in a preclinical bladder cancer xenograft model.
  • Data from preclinical studies of FPI-2059, a TAT designed to target and deliver actinium-225 to cancer cells expressing neurotensin receptor 1 (NTSR1), were presented in an oral presentation titled "NTSR1 Targeted Alpha Therapeutic [225Ac]-FPI-2059 induces regression in preclinical colorectal xenograft model".